Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRANCH-HF
2024-518438-94-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing PF-07328948 with Placebo (2 arms). Primary endpoint: Hierarchical composite efficacy endpoint through Week 36. Planned start Oct 2025; status: authorised.
02
Drugs
PF-07328948
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2024-518438-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518438-94-00.